论文部分内容阅读
目的探讨用白介素-8（IL－8）作配体，检测红细胞趋化因子受体（ECKR）结合活性及其临床意义。方法分离的红细胞与一定量的IL-8溶液结合，离心后取上清液用酶联免疫吸附试验（ELISA）检测IL－8含量，反映ECKR结合活性。结果34例正常人ECKR(红细胞数为3．0×1012／L）结合活性（±s％）为37．6±7．8，30例肝炎、31例肺癌、16例慢性肾功能衰竭和8例系统性红斑狼疮患者则分别为19．7±10．5、19．8±10．9、21．5±6．4和21．3±12．2。经统计，各疾病组ECKR结合活性明显低于正常人组（P＜0．01）。结论红细胞参与趋化因子的调控，在上述疾病的发病过程中可能起重要作用。临床上检测ECKR结合活性有其临床应用价值。
Objective To investigate the binding activity of erythrocyte chemokine receptor (ECKR) and its clinical significance with interleukin-8 (IL-8) as ligand. The erythrocytes isolated from the method were combined with a certain amount of IL-8 solution. After centrifugation, the supernatant was collected and the content of IL-8 was detected by enzyme-linked immunosorbent assay (ELISA) to reflect the ECKR binding activity. Results The binding activity (± s%) of ECKR (erythrocyte number 3.0 × 1012 / L) in 34 normal persons was 37.6 ± 7.8, 30 cases of hepatitis, 31 cases of lung cancer, 16 cases of chronic renal failure and 8 cases of chronic renal failure Patients with systemic lupus erythematosus were 19.7 ± 10.5,19.8 ± 10.9,21.5 ± 6.4 and 21.3 ± 12.2 respectively. The statistics showed that the ECKR binding activity of each disease group was significantly lower than that of the normal group (P <0.01). Conclusion The regulation of chemokines by erythrocytes may play an important role in the pathogenesis of these diseases. Clinical examination of ECKR binding activity has its clinical value.